ADGM recorded a substantial increase of 215% in total Assets Under Management (AUM) in Q3 2024 compared to Q3 2023, demonstrating its rapid ascent as a top asset management hub in the MENA region.

Cyber Monday is more than just a sale—it's Monport's way of encouraging creators to explore their potential with state-of-the-art laser technology. Known for their CO2 lasers, fiber lasers, diode ...

GlobeNewswire ...

On 29 November 2024, EDF (BBB positive S&P / Baa1 stable Moody's / BBB+ negative Fitch) signed a €6 billion syndicated credit facility for a five-year term, renewable twice for one year. Its cost will ...

Vantage Drilling International Ltd. (the “Company”) is pleased to announce the issue of an additional $50,000,000 in aggregate principal amount (the “additional notes” together with the notes ...

The Company is now in compliance with Nasdaq Listing Rule 5250 (f). Trading of the Company’s shares is unaffected and continues as usual.

The Inducement Award granted to Dr. Baker was an option to purchase 200,000 shares of common stock of the Company at an exercise price of $1.06 per share, representing the closing price of a share of ...

Triumph Financial, Inc. (Nasdaq: TFIN) is a financial holding company focused on payments, factoring and banking. Headquartered in Dallas, Texas, its diversified portfolio of brands includes ...

The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such ...

The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into ...

In response to the deterioration in lease rates for heritage office buildings, proactive measures were taken in recent years to adapt to the evolving market realities. In February 2024, we completed ...

Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc.